title: Does response inhibition have pre- and postdiagnostic utility in Parkinson's disease?
abstract: Parkinson's disease (Pd) is the second most prevalent degenerative neurological condition worldwide. Improving and sustaining quality of life is an important goal for Parkinson's patients. Key areas of focus to achieve this goal include earlier diagnosis and individualized treatment. In this review the authors discuss impulse control in Pd and examine how measures of impulse control from a response inhibition task may provide clinically useful information (a) within an objective test battery to aid earlier diagnosis of Pd and (b) in postdiagnostic Pd, to better identify individuals at risk of developing impulse control disorders with dopaminergic medication.
authors.affiliation: a Department of Sport and Exercise Science , University of Auckland , New Zealand.
authors.forename: Hayley J
authors.initials: HJ
authors.lastname: MacDonald
authors.forename: Winston D
authors.initials: WD
authors.lastname: Byblow
mesh_terms: D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced / Q000150:complications / Q000175:diagnosis* / Q000517:prevention & control; D015259:Dopamine Agents / Q000009:adverse effects; D042241:Early Diagnosis; D006801:Humans; D007266:Inhibition, Psychological; D009434:Neural Pathways / Q000503:physiopathology; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology*; D057285:Precision Medicine
chemical_list: D015259:Dopamine Agents
keywords: Parkinson's disease; biomarkers; impulse control disorders; individualized treatment; response inhibition